AND
Live / Applied — Fourth extension granted (statement of use) (as of 26 Feb 2026)
What this means for you
Not registered yet, but its 25 Oct 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97646752
- Mark type
- Stylized text
- Filed
- 25 Oct 2022
- Published for opposition
- 27 Feb 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 001 — Chemicals: Biological and chemical agents for scientific use other than for medical use, namely, addressable and programmable protein-based therapeutics
- Class 005 — Pharmaceuticals: Biological therapeutics, namely, addressable and programmable protein-based therapeutics, including multi-specific polypeptide-based therapeutics, namely, therapeutic pharmaceuticals for the treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders; pharmaceutical preparations, namely, addressable and programmable protein-based therapeutics, for treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders
- Class 042 — Scientific and technological services: Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services
Owner
- AMPERSAND BIOTECHNOLOGIES, INC., Cambridge, MA, US
- AMPERSAND BIOTECHNOLOGIES, INC., Boston, MA, US
- Flagship Labs 75, Inc., Cambridge, MA, US
Prosecution history
- 27 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Feb 2026 — SOU EXTENSION 4 GRANTED
- 26 Feb 2026 — SOU EXTENSION 4 FILED
- 26 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Oct 2025 — SOU EXTENSION 3 GRANTED
- 22 Oct 2025 — SOU EXTENSION 3 FILED
- 22 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Mar 2025 — SOU EXTENSION 2 GRANTED
- 12 Mar 2025 — SOU EXTENSION 2 FILED
- 12 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Jan 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 07 Jan 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 07 Jan 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED